

## **MedAnnex Attends the BioDundee Conference.**

### **Dundee, Scotland - 24 & 25th May 2016.**

Representatives from Edinburgh-based biotechnology company MedAnnex Ltd this week attended the 16th Annual International BioDundee Conference at Dundee's West Park Centre.

The two-day conference was organised by the Scottish Life Sciences Community and featured networking sessions, panel discussions and presentations by a wide range of eminent speakers, including physicians, academics and pharmaceutical entrepreneurs.

Dr Manuelle Debunne, Operations Director for MedAnnex, said: "BioDundee was a great opportunity for MedAnnex to connect with our Life Sciences colleagues from Scotland, the rest of the UK and beyond. As we continue to develop our antibody, Annexuzlimab, as a novel treatment for people with autoimmune diseases, it's important that we keep up-to-date with new ideas and developments, and conferences such as this are an excellent way to do that."

#### About MedAnnex

MedAnnex Ltd, based in Scotland, is a dynamic biotechnology company developing new therapies for the treatment of autoimmune diseases.

#### About Annexuzlimab®

Annexuzlimab, MedAnnex's lead product, is a humanised monoclonal antibody. Its target is annexin-1, which is over-expressed in autoimmune disease and is a key factor in the human immune system. Blocking annexin-1 with Annexuzlimab, in experimental models, has reversed the progression of several autoimmune diseases.